SPH21 Antibody

Introduction to SPHK1 and Its Antibodies

Sphingosine Kinase 1 (SPHK1) catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P), a bioactive lipid regulating cellular processes such as proliferation, apoptosis, and immune responses . Antibodies against SPHK1 are pivotal for studying its role in cancer, inflammation, and metabolic disorders.

Table 1: Key SPHK1 Antibody Features

Mechanistic Studies

• Cancer: SPHK1 overexpression in tumors correlates with chemoresistance and metastasis. Antibodies like SP1621 detect upregulated SPHK1 in breast and colon cancer models .

• Cardiovascular Disease: SPHK1 inhibition reduces cardiac hypertrophy in mice, validated via WB using PA5-28584 .

• Neuroinflammation: Nuclear SPHK1 modulates histone deacetylase activity, identified using ab175553 in neuronal cultures .

Technical Validation

• Specificity: SP1621 shows no cross-reactivity with SPHK2 in SK1-null mice .

• Sensitivity: PA5-28584 detects SPHK1 at 1:1,000 dilution in HeLa and HepG2 lysates .

Clinical Relevance

• Biomarker Potential: SPHK1 levels in serum, measured via ELISA (PA5-28584), predict survival in lung cancer patients .

• Therapeutic Targeting: Anti-SPHK1 antibodies enhance efficacy of tyrosine kinase inhibitors in preclinical models .

Table 2: Clinical Findings Using SPHK1 Antibodies

Limitations and Future Directions

• Species Cross-Reactivity: Most antibodies (e.g., SP1621) are human-specific; murine studies require ab175553 .

• Epitope Masking: Fixed tissues may require antigen retrieval for IHC .